SOMATOSTATIN ANALOGUES VS ACTIVE SURVEILLANCE IN SMALL PANCREATIC NEUROENDOCRINE TUMORS.
| Autor: | Maratta MG, Chiloiro S, Raia S, Maiorano BA; Roma European NeuroEndocrine Tumor Society (ENETS) Center of Excellence for the Diagnosis and Cure of Neuroendocrine Tumors, Rome, Italy., Horn G, Brizi MG, Rufini V, Giancipoli RG, De Marinis L, Bianchi A, Pontecorvi A, Schinzari G, Inzani F, Tortora G, Rindi G |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Pancreas [Pancreas] 2024 Nov 28. Date of Electronic Publication: 2024 Nov 28. |
| DOI: | 10.1097/MPA.0000000000002425 |
| Abstrakt: | Objectives: The best strategy for non-functioning, sporadic, G1-G2 pancreatic neuroendocrine tumors ≤2 cm is unknown. An active surveillance is usually recommended. The PROMID and the CLARINET studies proved the value of somatostatin analogue (SSA) treatment in advanced gastro-entero-pancreatic neuroendocrine tumors. Aim of this study is to assess the value of SSA in PanNET≤2 cm. Methods: We retrospectively collected data from 72 patients with sporadic non-functioning G1-G2 PanNETs≤2 cm, that were either treated with somatostatin analogues (n = 31) or underwent active surveillance (n = 41) at our Institution. Results: At a median follow-up of 53.7 months, the median progression free survival was not reached in the treatment group versus an estimated PFS of 85 months in the control group (HR 0.11, p = 0.01), with a rate of progression or death up to 21.9% in the active surveillance group. Additionally, in the group of patients treated with somatostatin analogues the response rate was 16.1% with one complete response. Conclusions: Our monocentric experience demonstrated a significant antiproliferative activity of somatostatin analogues in patients with sporadic, non-functionating G1-G2 PanNETs ≤2 cm delaying tumor progression and distant spread in small lesions that sometimes may reveal unpredictable aggressiveness. Competing Interests: CONFLICT OF INTEREST: GR received speaker and consultant honoraria from AAA and Bracco Imaging. The other authors declare that they have no conflict of interest. (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|